文献速递认知障碍与谵妄衰弱、肌少症与跌倒

CCL2与CXCL2是社区老年人谵妄易感性的标志物

CCL2 and CXCL2 are markers of delirium vulnerability in community dwelling older people.
PubMed 文献 · Age Ageing · 2026-01-01

该研究在社区老年人中比较了2年内发生与未发生谵妄者基线的免疫细胞迁移标志物。98名参与者中43.9%发生至少1次谵妄,基线的CCL2与CXCL2在谵妄组显著更高,CCL2的关联在痴呆与非痴呆亚组中均维持,CXCL2仅在非痴呆亚组显著。

要点

  • 社区老年人基线CCL2与CXCL2升高与2年内谵妄发生相关。
  • CCL2与谵妄的关联在有无痴呆者中均存在。
  • CXCL2仅在无痴呆亚组中与谵妄显著相关。

核心结论

  • CCL2与CXCL2是参与免疫细胞募集和加速免疫衰老的趋化因子,可能标志社区老年人的谵妄易感性。

研究设计与样本

  • 研究纳入CASCADE队列中随访2年的社区居住老年人,基线采血并用多重panel检测血清标志物,每周进行谵妄筛查,阳性筛查或入院触发谵妄评估。
  • 共纳入98名参与者,中位年龄88岁(IQR:81.8-92.0),90.8%被归类为衰弱。

主要发现

  • 43名参与者(43.9%)在2年内经历至少1次谵妄发作。
  • 基线稳定状态下,谵妄组CCL2(MCP-1)显著高于无谵妄组:13.38(11.21-17.93)vs. 10.83(9.03-14.64),P = .004。
  • 基线稳定状态下,谵妄组CXCL2(MIP-2α)显著高于无谵妄组:17.23(11.80-24.22)vs. 13.49(10.19-17.98),P = .031。
  • 按痴呆状态分层后,CCL2与谵妄的关联在两组中均维持,而CXCL2仅在无痴呆亚组中显著升高。

临床怎么用

  • 对社区老年人,基线CCL2与CXCL2升高提示谵妄易感性增加,可据此识别高危个体。
  • 未来需阐明免疫细胞募集与脑内浸润在谵妄中的作用,以寻找治疗靶点。
  • 可探索靶向免疫衰老是否能降低谵妄风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delirium is common and age, frailty and dementia are risk-factors. The pathophysiology is complex and poorly understood, but age-related immune system changes may be key. This study aimed to measure markers of immune cell migration, accelerated immune ageing and blood-brain barrier permeability in community-dwelling, older people comparing those who developed ≥1 episode of delirium over 2 years with those that did not. METHODS: Baseline samples were collected from CASCADE participants who were followed up for 2 years. Delirium screening was performed weekly; positive screens or hospital admission triggered a delirium assessment. Serum was isolated, stored and analysed using a multiplex panel comparing levels between participants with and without delirium episodes. RESULTS: About 98 participants were included. Median age was 88 (IQR: 81.8-92.0), with 90.8% classified as frail. Forty-three participants (43.9%) experienced ≥1 delirium episodes. CCL2 (MCP-1) and CXCL2 (MIP-2α), measured in a stable state at baseline, were significantly higher in the delirium group compared to the no delirium group (13.38 (11.21-17.93) vs. 10.83 (9.03-14.64) P = .004) and (17.23 (11.80-24.22) vs. 13.49 (10.19-17.98) P = .031), respectively. When stratified by dementia status, the associations of CCL2 with delirium were maintained in both groups, but CXCL2 was only significantly higher in delirium in the subgroup without dementia. DISCUSSION: CCL2 and CXCL2 are chemokines involved in immune cell recruitment and markers of accelerated immune ageing. Future work should elucidate the role of immune cell recruitment and brain infiltration in delirium, to identify treatment targets. Furthermore, work should explore whether targeting immune ageing can reduce delirium risk.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Moorey H, Botfield HF, Krogseth M, et al. CCL2 and CXCL2 are markers of delirium vulnerability in community dwelling older people. Age Ageing. 2026. PMID: 42814578. doi:10.1093/ageing/afag290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。